Canurta.ethThe Satoshi Trials™: A Bitcoin Treasury Reserve Thesis
Date of Original Draft: Dec 15, 2024. Special Note: The initial Bitcoin price considered for these calculations is $100,000 USD per BTC given we [had on Dec 15th, 2024] passed the psychological price benchmark. Setting the Stage for Disruption Biotechnology has long grappled with the high costs and uncertainty of drug development, leaving promising therapies for diseases like ALS underfunded. At Canurta, we recognize the need for a transformative approach—one that not only addresses these cha...
Canurta.ethThe Canurta White Paper: Grounds for Further Investigation into Hemp Polyphenols
Written by Akeem Gardner, LLB Originally published on September 28, 2021 in Canurta’s Journal A quick note from Akeem before we begin: “2021 was an amazing year. From the launch of our company we grew by acquiring additional IP and investors who are supporting our mission to heal the world with novel polyphenols that have never been clinically explored before. Our team has shown so much growth in our journey of discovery and learning, and it’s now time to implement our DeSci strategy for our ...
Canurta.ethBuilt to Last, Not to Flex
A Founder's Note — Akeem Gardner"Thus, the deluded Bankrupt raves; Puts all upon a desprate Bet; Then plunges in the Southern Waves; Dipt over Head and Ears—in Debt."Life has a unique way of guiding us exactly where we need to be, often without us fully realizing it at the time. My journey led me to study law at the University of Kent, Canterbury, a path seemingly unrelated to my core passion—innovation and entrepreneurship. Yet, it was precisely in my Company Law class in October 2015 w...
an emerging biotech company using rare hemp polyphenols and DeSci to create safe and effective natural therapeutics
To the Canurta community & Bitcoin enthusiasts
Today marks a defining moment in Canurta’s journey—our first Satoshi Trials™ loan, secured directly against our Bitcoin treasury, has closed. On May 13, 2025, we leveraged 0.34765 BTC as Collateral with APX Lending for a simple fixed-rate facility, showcasing our innovative R&D Strategy. These funds immediately kick-start our new R&D partnership with TransBioTech, where we’ll embark on a two-part preclinical program (toxicology and BBB penetration studies) for CNR-401, our lead adaptive-medicine candidate, for the treatment of ALS.
Why does this matter? By pledging Bitcoin—rather than diluting equity or mortgaging physical assets—we’ve unlocked capital in a matter of days. The APX process was seamless: no lengthy covenants, no appraisal delays, no board sign-offs on heavy equipment—just a swift drawdown that puts cash in our account when and where R&D demands it. Compare that to a traditional equipment or real-estate loan: paperwork meanders for weeks, if not months; covenants drag you into endless negotiations; and interest rates are often higher.
From here, our funding stack will blend:
R&D tax credits to reimburse eligible research spend,
Shareholder support via modest revenue‐share or royalty structures, and
Bitcoin appreciation as an offset to financing costs.
Over the life of this loan, any appreciation in our BTC holdings directly reduces net borrowing costs—turning a liability into another potential value driver. More importantly, we’ll demonstrate that a Canadian biotech can sustainably leverage Bitcoin on its balance sheet to accelerate ALS research without excessive dilution and continued fundraising in dire funding climates.
To our investors, this transaction signals that Canurta is not just innovating in the lab, but innovating in finance. We’re building a blueprint where cutting-edge adaptive medicine is underwritten by best-in-class treasury management—bridging digital-asset finance with life-science impact. This is exactly the kind of agility our industry needs to outpace clinical timelines and deliver life-changing therapies.
We look forward to sharing data as our TransBioTech studies progress and showcasing how each preclinical milestone parallels growth in shareholder value. Thank you for your continued trust as we pioneer the Satoshi Trials™ model, fighting ALS and other complex diseases by marrying biotech rigor with Bitcoin’s financial power. We look forward to sharing our success on this journey and the results of the research as we continue from here.
Onward with focus and intention,
Akeem Gardner | CEO & Founder | Canurta Therapeutics
To the Canurta community & Bitcoin enthusiasts
Today marks a defining moment in Canurta’s journey—our first Satoshi Trials™ loan, secured directly against our Bitcoin treasury, has closed. On May 13, 2025, we leveraged 0.34765 BTC as Collateral with APX Lending for a simple fixed-rate facility, showcasing our innovative R&D Strategy. These funds immediately kick-start our new R&D partnership with TransBioTech, where we’ll embark on a two-part preclinical program (toxicology and BBB penetration studies) for CNR-401, our lead adaptive-medicine candidate, for the treatment of ALS.
Why does this matter? By pledging Bitcoin—rather than diluting equity or mortgaging physical assets—we’ve unlocked capital in a matter of days. The APX process was seamless: no lengthy covenants, no appraisal delays, no board sign-offs on heavy equipment—just a swift drawdown that puts cash in our account when and where R&D demands it. Compare that to a traditional equipment or real-estate loan: paperwork meanders for weeks, if not months; covenants drag you into endless negotiations; and interest rates are often higher.
From here, our funding stack will blend:
R&D tax credits to reimburse eligible research spend,
Shareholder support via modest revenue‐share or royalty structures, and
Bitcoin appreciation as an offset to financing costs.
Over the life of this loan, any appreciation in our BTC holdings directly reduces net borrowing costs—turning a liability into another potential value driver. More importantly, we’ll demonstrate that a Canadian biotech can sustainably leverage Bitcoin on its balance sheet to accelerate ALS research without excessive dilution and continued fundraising in dire funding climates.
To our investors, this transaction signals that Canurta is not just innovating in the lab, but innovating in finance. We’re building a blueprint where cutting-edge adaptive medicine is underwritten by best-in-class treasury management—bridging digital-asset finance with life-science impact. This is exactly the kind of agility our industry needs to outpace clinical timelines and deliver life-changing therapies.
We look forward to sharing data as our TransBioTech studies progress and showcasing how each preclinical milestone parallels growth in shareholder value. Thank you for your continued trust as we pioneer the Satoshi Trials™ model, fighting ALS and other complex diseases by marrying biotech rigor with Bitcoin’s financial power. We look forward to sharing our success on this journey and the results of the research as we continue from here.
Onward with focus and intention,
Akeem Gardner | CEO & Founder | Canurta Therapeutics
Canurta.ethThe Satoshi Trials™: A Bitcoin Treasury Reserve Thesis
Date of Original Draft: Dec 15, 2024. Special Note: The initial Bitcoin price considered for these calculations is $100,000 USD per BTC given we [had on Dec 15th, 2024] passed the psychological price benchmark. Setting the Stage for Disruption Biotechnology has long grappled with the high costs and uncertainty of drug development, leaving promising therapies for diseases like ALS underfunded. At Canurta, we recognize the need for a transformative approach—one that not only addresses these cha...
Canurta.ethThe Canurta White Paper: Grounds for Further Investigation into Hemp Polyphenols
Written by Akeem Gardner, LLB Originally published on September 28, 2021 in Canurta’s Journal A quick note from Akeem before we begin: “2021 was an amazing year. From the launch of our company we grew by acquiring additional IP and investors who are supporting our mission to heal the world with novel polyphenols that have never been clinically explored before. Our team has shown so much growth in our journey of discovery and learning, and it’s now time to implement our DeSci strategy for our ...
Canurta.ethBuilt to Last, Not to Flex
A Founder's Note — Akeem Gardner"Thus, the deluded Bankrupt raves; Puts all upon a desprate Bet; Then plunges in the Southern Waves; Dipt over Head and Ears—in Debt."Life has a unique way of guiding us exactly where we need to be, often without us fully realizing it at the time. My journey led me to study law at the University of Kent, Canterbury, a path seemingly unrelated to my core passion—innovation and entrepreneurship. Yet, it was precisely in my Company Law class in October 2015 w...
Share Dialog
Share Dialog
an emerging biotech company using rare hemp polyphenols and DeSci to create safe and effective natural therapeutics
Subscribe to Canurta.eth
Subscribe to Canurta.eth
<100 subscribers
<100 subscribers
No activity yet